Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia®, Inc., announced today it will share new data from the ongoing prospective, observational FLEX Trial (NCT03053193) in two poster presentations at the 41st Annual Miami Breast Cancer Conference (MBCC), taking place March 7 – 10th, 2024. The first poster, titled MammaPrint® and BluePrint® predict anthracycline…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks